Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (otvara novi prozor)

CRASH-3 Trial Collaborators

Izvor‎: Lancet 2019;394(10210):1713-23.

Indeks‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (otvara novi prozor)

Alternatives to allogeneic platelet transfusion. (otvara novi prozor)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (otvara novi prozor)

Tranexamic acid: less bleeding and less thrombosis? (otvara novi prozor)

Godier A, Roberts I, Hunt BJ.

Izvor‎: Crit Care 2012;16(3):135.

Indeks‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (otvara novi prozor)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (otvara novi prozor)

Perel P, Ker K, Morales Uribe CH, Roberts I

Izvor‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Indeks‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (otvara novi prozor)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (otvara novi prozor)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Izvor‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Indeks‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (otvara novi prozor)

Antifibrinolytic drugs for acute traumatic injury. (otvara novi prozor)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Izvor‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Indeks‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (otvara novi prozor)

Use of tranexamic acid to reduce bleeding in burns surgery. (otvara novi prozor)

Tang YM, Chapman TW, Brooks P

Izvor‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Indeks‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (otvara novi prozor)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (otvara novi prozor)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Izvor‎: Burns. 2022;48(3):522-28.

Indeks‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (otvara novi prozor)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (otvara novi prozor)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Izvor‎: J Blood Med 2011;2:131-4.

Indeks‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (otvara novi prozor)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (otvara novi prozor)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Izvor‎: Transfusion 2009;49 Suppl 5:240S-7S.

Indeks‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (otvara novi prozor)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (otvara novi prozor)

Fries D

Izvor‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indeks‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (otvara novi prozor)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (otvara novi prozor)

Haan J, Scalea T

Izvor‎: Am Surg 2005;71(5):414-5.

Indeks‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (otvara novi prozor)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (otvara novi prozor)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Izvor‎: J Trauma 2010;69(3):489-500.

Indeks‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (otvara novi prozor)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (otvara novi prozor)

Hsia CC, Chin-Yee IH, McAlister VC.

Izvor‎: Ann Surg 2008;248(1):61-8.

Indeks‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (otvara novi prozor)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (otvara novi prozor)

Johansson PI, Eriksen K, Alsbjørn B

Izvor‎: J Trauma 2006;61(4):1016-8.

Indeks‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (otvara novi prozor)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (otvara novi prozor)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Izvor‎: ANZ J Surg 2013;83(3):155-60.

Indeks‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (otvara novi prozor)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (otvara novi prozor)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Izvor‎: Injury 2012;43(9):1409-14.

Indeks‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (otvara novi prozor)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (otvara novi prozor)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Izvor‎: Injury 2008;39(9):1054-61.

Indeks‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (otvara novi prozor)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (otvara novi prozor)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Izvor‎: Anesthesiology 2003;98(6):1513-5.

Indeks‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (otvara novi prozor)

Alternatives to allogeneic platelet transfusion. (otvara novi prozor)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (otvara novi prozor)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (otvara novi prozor)

Fries D

Izvor‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indeks‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (otvara novi prozor)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (otvara novi prozor)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Izvor‎: Thromb Res 2014;134(2):360-8.

Indeks‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (otvara novi prozor)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (otvara novi prozor)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Izvor‎: Br J Haematol 2013;160(2):228-36.

Indeks‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (otvara novi prozor)

Strategies to reduce the use of blood products: a European perspective. (otvara novi prozor)

Theusinger OM, Felix C, Spahn DR.

Izvor‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Indeks‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (otvara novi prozor)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (otvara novi prozor)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Izvor‎: Anesthesiology 2008;109(6):1063-76.

Indeks‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (otvara novi prozor)

Alternatives to allogeneic platelet transfusion. (otvara novi prozor)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Izvor‎: Br J Haematol 2016;175(3):381-92.

Indeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (otvara novi prozor)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (otvara novi prozor)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Izvor‎: Blood Rev 2014;28(3):95-102.

Indeks‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (otvara novi prozor)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (otvara novi prozor)

Alperin JB

Izvor‎: JAMA 1987;258(14):1916-9.

Indeks‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (otvara novi prozor)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (otvara novi prozor)

Crowther MA, McDonald E, Johnston M, Cook D

Izvor‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Indeks‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (otvara novi prozor)

The use of fibrin sealant in burn operations. (otvara novi prozor)

Foster K

Izvor‎: Surgery 2007;142(4 Suppl):S50-4.

Indeks‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (otvara novi prozor)

Use of fibrin sealant in thermal injury. (otvara novi prozor)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Izvor‎: J Burn Care Rehabil 1997;18(5):429-34.

Indeks‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (otvara novi prozor)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (otvara novi prozor)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Izvor‎: Br J Anaesth 2012;109(3):376-81.

Indeks‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (otvara novi prozor)

Transfusion in trauma: why and how should we change our current practice? (otvara novi prozor)

Theusinger OM, Spahn DR, Ganter MT.

Izvor‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Indeks‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (otvara novi prozor)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (otvara novi prozor)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Izvor‎: Health Technol Assess 2015;19(58):1-228.

Indeks‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (otvara novi prozor)